ArticleBMC nephrology2026
Collapsing FSGS in a kidney transplant with a single APOL1 risk variant: a case report.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApolipoprotein L1 (APOL1) genetic risk variants substantially increase the risk of chronic kidney disease and kidney failure among individuals of recent African ancestry. While APOL1-associated nephropathy was long considered to follow a recessive inheritance pattern, recent studies have demonstrated an additive effect, indicating that even a single risk variant may be clinically significant. A severe manifestation of APOL1-mediated kidney disease, collapsing focal segmental glomerular sclerosis, has been reported mainly in allografts from donors with two risk variants. CASE PRESENTATION: A 60-year-old Surinamese woman of West-African descent with end-stage kidney disease of unknown origin received a kidney transplant from her daughter, with pre-existing donor-specific Class II antibodies detected. The patient experienced delayed graft function, active antibody-mediated rejection, and ultimately developed collapsing focal segmental glomerular sclerosis. Despite intensive treatment, the graft failed, necessitating transplantectomy. Genetic testing revealed a G1G1 APOL1 genotype in the recipient and G1G0 in the donor.
conclusionsThis case suggests that both donor and recipient APOL1 genotypes can contribute to the development of APOL1-mediated kidney disease post-transplantation, and highlights the potential risk associated with even a single APOL1 risk variant in the donor as well as the possible role of the recipient’s APOL1 genotype affecting the immune system. These observations support the consideration of routine APOL1 genotyping in donors of West-African ancestry to improve transplant safety and risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.